Commonwealth Bank of Australia lifted its position in Humana Inc. (NYSE:HUM) by 4.0% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 20,316 shares of the insurance provider’s stock after buying an additional 775 shares during the period. Commonwealth Bank of Australia’s holdings in Humana were worth $4,887,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently bought and sold shares of the company. BlackRock Inc. raised its stake in shares of Humana by 2,281.7% in the 1st quarter. BlackRock Inc. now owns 12,387,144 shares of the insurance provider’s stock worth $2,553,487,000 after buying an additional 11,867,056 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Humana by 3.6% during the first quarter. Vanguard Group Inc. now owns 9,734,767 shares of the insurance provider’s stock worth $2,006,725,000 after purchasing an additional 339,620 shares during the period. State Street Corp raised its position in shares of Humana by 1.4% during the first quarter. State Street Corp now owns 6,274,811 shares of the insurance provider’s stock worth $1,293,487,000 after purchasing an additional 84,716 shares during the period. FMR LLC raised its position in shares of Humana by 57.9% during the first quarter. FMR LLC now owns 5,050,853 shares of the insurance provider’s stock worth $1,041,184,000 after purchasing an additional 1,851,197 shares during the period. Finally, Renaissance Technologies LLC raised its position in shares of Humana by 84.3% during the first quarter. Renaissance Technologies LLC now owns 2,691,700 shares of the insurance provider’s stock worth $554,867,000 after purchasing an additional 1,231,400 shares during the period. 95.14% of the stock is currently owned by institutional investors.
Humana Inc. (NYSE:HUM) traded down 0.55% during mid-day trading on Friday, hitting $249.28. The stock had a trading volume of 1,228,357 shares. Humana Inc. has a 52 week low of $163.50 and a 52 week high of $259.76. The stock’s 50-day moving average is $250.25 and its 200 day moving average is $231.50. The company has a market capitalization of $36.03 billion, a P/E ratio of 20.51 and a beta of 0.87.
Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.08 by $0.41. The company had revenue of $13.53 billion during the quarter, compared to analysts’ expectations of $13.61 billion. Humana had a return on equity of 15.85% and a net margin of 3.37%. During the same quarter last year, the company earned $2.30 EPS. Equities analysts forecast that Humana Inc. will post $11.55 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Tuesday, August 29th will be issued a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 0.64%. The ex-dividend date is Thursday, September 28th. Humana’s payout ratio is 13.06%.
In related news, CEO Bruce D. Broussard sold 12,000 shares of Humana stock in a transaction dated Friday, August 11th. The stock was sold at an average price of $251.88, for a total transaction of $3,022,560.00. Following the completion of the transaction, the chief executive officer now owns 80,086 shares in the company, valued at $20,172,061.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider William Kevin Fleming sold 3,071 shares of Humana stock in a transaction dated Wednesday, August 23rd. The stock was sold at an average price of $250.98, for a total value of $770,759.58. Following the transaction, the insider now owns 7,681 shares of the company’s stock, valued at approximately $1,927,777.38. The disclosure for this sale can be found here. Insiders sold a total of 60,566 shares of company stock valued at $15,326,746 in the last 90 days. 0.80% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: This article was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://ledgergazette.com/2017/09/17/commonwealth-bank-of-australia-grows-holdings-in-humana-inc-hum.html.
A number of equities research analysts have recently issued reports on HUM shares. Citigroup Inc. started coverage on Humana in a research report on Wednesday, June 28th. They set a “buy” rating and a $275.00 target price on the stock. BidaskClub lowered Humana from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. Zacks Investment Research raised Humana from a “hold” rating to a “buy” rating and set a $257.00 target price on the stock in a research report on Thursday, May 25th. Argus upgraded Humana from a “hold” rating to a “buy” rating and set a $260.00 price target on the stock in a report on Friday, June 9th. Finally, ValuEngine upgraded Humana from a “hold” rating to a “buy” rating in a report on Friday, September 1st. One research analyst has rated the stock with a sell rating, nine have given a hold rating and thirteen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $244.35.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Humana Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.